טוען...
Prolonged Hypocalcemia After a Single Dose of Denosumab in Chronic Kidney Disease
Introduction: Denosumab, a monoclonal antibody that inhibits RANK L (receptor activator nuclear factor-kappa beta ligand), is one of the few medications that can be used to treat osteoporosis in patients with chronic kidney disease (CKD). However, its use is associated with a much higher incidence o...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089260/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.439 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|